Table 1

Patient demographics and response

Patient ID	Dose (µg)	Weight (kg)	Age (years)	Sex	Disease	Breed	Best response	Response duration (days)	Survival from first IL-15 (days)
IL-15–001	10	32.2	7.6	MC	OSA	Golden retriever	NE		37
IL-15–002	10	49.0	11.1	MC	OSA	Golden retriever	SD	55	105
IL-15–003	10	47.6	8.6	FS	OSA	Labrador mix	PD		655
IL-15–004	10	28.3	11.0	FS	OSA	Golden retriever	PR	85	98
IL-15–005	10	23.4	12.3	MC	OSA	Shepherd mix	SD	46	67
IL-15–006	10	21.2	11.3	FS	OSA	Shepherd mix	PD		54
IL-15–007	20	29.5	7.5	MC	MEL	Boxer	NE		14
IL-15–008	20	21.3	13.7	FS	OSA	Greyhound	NE		21
IL-15–009	20	34.2	12.8	FS	OSA	German Shorthaired Pointer	PD		36
IL-15–010	33	25.2	10.8	FS	MEL	Golden retriever	PD		58
IL-15–011	33	27.9	12.3	MC	OSA	Border collie mix	PD		310
IL-15–012	33	26.6	9.7	MI	MEL	Irish water spaniel	PD		70
IL-15–013	50	35.4	11.1	MC	MEL	Pit bull mix	SD	147	336
IL-15–014	50	39.3	12.6	FS	MEL	Labrador	CR	350	407
IL-15–015	50	33.3	11.6	FS	MEL	Mix	SD	56	130
IL-15–016	70	46.3	8.5	MC	MEL	Mix	PD		38
IL-15–017	70	34.7	9.7	MC	MEL	Doberman	PD		227
IL-15–018	70	21.5	12.7	FS	MEL	Terrier mix	SD	42	154
IL-15–019	70	8.5	13.8	MC	MEL	Mix	PD		34
IL-15–020	70	34.5	12.7	MC	MEL	Labrador	PD		97
IL-15–021	70	24.5	3.0	MI	OSA	Belgian sheepdog	PD		39

CR, complete response; FS, female spayed; IL-15, interleukin-15; MC, male castrated; MEL, melanoma; MI, male intact; NE, not evaluable; OSA, osteosarcoma; PD, progressive disease; PR, partial response; SD, stable disease.